Managing resistance to analogue antiviral drugs in the treatment of chronic hepatitis B;Prise en charge de la résistance aux antiviraux dans le traitement de l'hépatite chronique B

Gastroenterologie Clinique et Biologique

Volumn 30, Issue 10 C2, 2006, Pages

  Marcellin, Patrick ^a,b   Lada, Olivier ^a  

^a BEAUJON HOSPITAL   (France)

^b CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; CLEVUDINE; EMTRICITABINE; ENTECAVIR; LAMIVUDINE; PEGINTERFERON ALPHA2A; PRADEFOVIR; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; VALTORCITABINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

DRUG EFFICACY; EDITORIAL; GENE MUTATION; HEPATITIS B; HISTOPATHOLOGY; HUMAN; NONHUMAN; VIROLOGY; ANTIBIOTIC RESISTANCE; DRUG COMBINATION; DRUG EFFECT; GENETICS; HEPATITIS B VIRUS; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 33846023000     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0399-8320(06)73522-9     Document Type: Editorial

References (33)

1. EASL International Consensus Conference on Hepatitis B. Consensus Statement. J Hepatol 2003;39:S3-S25.
2. Conjeevaram HS, Lok AS. Management of chronic hepatitis B. J Hepatol 2003;38:S90-S103.
3. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. An Inter Med 1993;119:312-323.
4. Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10:298-305.
5. Marcellin P, Lau GKK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351:1206-17.
6. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-9.
7. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-95.
8. Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005;142:240-50.
9. Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res 2004;64:1-15.
10. Nicoll A, Locarnini S. Review: Present and future directions in the treatment of chronic hepatitis B infection. J Gastroenterol Hepatol 1997;12:843-54.
11. Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000;32:828-34.
12. Papatheodoridis GV, Dimou E, Dimakopoulos K, Manolakopoulos S, Rapti I, Kitis G, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005;42:121-9.
13. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31.
14. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002;36:219-26.
15. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16.
16. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis Be antigen- hepatitis B. N Engl J Med 2003;348:800-7.
17. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005;352:2673-81.
18. Marcellin P, Asselah T. Resistance to adefovir: a new challenge in the treatment of chronic hepatitis B. J Hepatol 2005;43:920-3.
19. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001-10.
20. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20. Erratum in: N Engl J Med. 2006;354:1863.
21. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, et al. Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B. Gastroenterology 2006;130:2039-49.
22. Fares MA, Holmes EC. A revised evolutionary history of hepatitis B virus (HBV). J Mol Evol 2002;54:807-14.
23. Park, S G, Kim Y, Park E, Ryu H M, Jung G. Fidelity of hepatitis B virus polymerase. Eur J Biochem 2003;270:2929-36.
24. Das K, Xiong X, Yang H, Westland CE, Gibbs C S, Sarafianos SG, Arnold E. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 2001;75:4771-9.
25. Bartholomeusz A, Tehan BG, Chalmers DK. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antiv Ther 2004;9:149-60.
26. Zoulim, F. Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance? Antivir Chem Chemother 2004;15:299-305.
27. Schildgen O, Sirma H, Funk A, Olotu C, Wend UC, Hartmann H, Helm M, Rockstroh JK, Willems WR, Will H, Gerlich WH. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006;354:1807-12.
28. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al. Telbivudine Phase II Investigator Group. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis Be antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528-36.
29. Van Bommel F, Wunsche T, Mauss S, Reinke P, Bergk A, Schurmann D, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004;40:1421-5.
30. Marcellin P, Mommeja-Marin H, Sacks SL, Lau GK, Sereni D, et al. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 2004;40:140-8.
31. Lin CC, Xu C, Teng A, Yeh LT, Peterson J. Pharmacokinetics of pradefovir and PMEA in healthy volunteers after oral dosing of pradefovir. J Clin Pharmacol 2005;45:1250-8.
32. Durantel D, Brunelle MN, Gros E, Carrouee-Durantel S, Pichoud C, Villet S, et al. Resistance of human hepatitis B virus to reverse transcriptase inhibitors : from genotypic to phenotypic testing. J Clin Virol 2005;34: S34-43.
33. Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 2004;9:353-63.